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Ipilimumab, an anti-CTLA-4 monoclonal antibody, has been shown to improve overall survival in patients with
metastatic melanoma. Preliminary data suggest that patients who fail BRAF inhibitor treatment experience a very
rapid progression of disease. Such selectivity for more rapid disease progression may mean these patients do not
receive the same benefit from subsequent treatment with ipilimumab as patients without prior BRAF inhibitor
treatment. The current challenge is focused on how to identify and approach the two populations of fast and slow
progressors and recent hypothesis suggest that treatment choice could be guided by baseline risk factors.
However, no data have yet defined which the best sequence is and more research is needed to identify predictors
of response in patients with metastatic melanoma to help guide whether a BRAF inhibitor or ipilimumab should be
used first in sequential therapy.Commentary
The recent availability of new drugs for the treatment
of patients with metastatic melanoma has profoundly
changed the therapeutic approach to a disease with previ-
ously poor prognosis, in which no drug had increased sur-
vival in randomized trials for over 30 years.
However, the introduction of novel drugs into clinical
practice can rapidly generate new data, offering extra
insights into their therapeutic use. This is currently hap-
pening in metastatic melanoma, where recent experience
has indicated that around half of patients receiving
BRAF inhibitors do not gain the same benefit from sub-
sequent treatment with ipilimumab as BRAF inhibitor
treatment-naïve patients. This may be a result of BRAF
inhibitor drug resistance activating some process of cel-
lular/metabolic escape, thus selecting a more aggressive
disease.
Ipilimumab has been shown to improve overall sur-
vival in approximately 80% of patients with metastatic
melanoma who have not received prior therapy with
BRAF inhibitors [1]. The remaining 20% who did not re-
spond appeared to be those who received only one or* Correspondence: paolo.ascierto@gmail.com
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reproduction in any medium, provided the ortwo doses of ipilimumab. Consistent with this, analysis
of around 900 patients who were treated in Italy within
a compassionate expanded access program revealed that
approximately 23% of patients were not able to continue
beyond the second ipilimumab administration [2]. These
findings are in agreement with its mechanism of action,
since by acting as an “activator” of the immune system
and not as a cytotoxic drug, ipilimumab requires a la-
tency period in order to show efficacy. Both these data-
sets included patients regardless of BRAF mutational
status, with mutation analysis not being performed in all
patients due to the absence of drugs against this target
at the time. However, as the population with this muta-
tion corresponds to approximately half of the total, it is
likely to assume that wild-type and mutated patients
were equally represented.
Although preliminary, recent data suggest that patients
who fail BRAF inhibitor treatment experience a very
rapid evolution and progression of disease. The BRIM2
study reported that in 16 of 39 patients (41%) who died
as a result of disease progression, death occurred within
28 days after the last administration of the drug [3].
Similarly, in the BRIM3 study, 22 of 42 patients (52%)
treated with vemurafenib died during the course of the
study within 28 days after the last administration, mainly
due to disease progression [4].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Different evidences of rapid progression disease




with a rapid disease
progression kinetics
BRIM-2 [3] 39 41%
BRIM-3 [4] 42 52%
Ascierto et al. [5] 28 43%
Ackerman et al. [6] 32 50%
Italian ipilimumab EAP [2] 54 41%
Fisher et al. [7] 42 38%
EAP: Expanded access program.
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http://www.translational-medicine.com/content/11/1/61In a retrospective analysis by our group, 12 of 28
patients (43%) treated with a BRAF inhibitor had rapid
disease progression meaning subsequent treatment with
ipilimumab was limited to only one or two administra-
tions and could not be completed [5]. An ECOG PS of
1, LDH level ≥1.10 times the upper limit of normal
(ULN) and the presence of brain metastases were all as-
sociated with not completing the ipilimumab induction
regimen. Similarly, Ackerman et al. reported that ap-
proximately 50% of patients who received ipilimumab
after progression on vemurafenib died within 4 months
[6], while the Royal Marsden Hospital reported that 38%
of patients who failed on vemurafenib were not able to
complete a second line treatment due to the rapid pro-
gression of disease [7]. In addition, in the compassionate
use program of ipilimumab in Italy, it was observed that
41% of 54 patients who had received prior treatment
with BRAF inhibitors did not receive a third dose of
ipilimumab [2].
In conclusion, although these data are still preliminary
and obtained from limited numbers of patients, taken
together they suggest that around half of patients (range
38–52%) that fail treatment with a BRAF inhibitor have
a much more rapid disease progression than those who
have not received BRAF inhibitor therapy (Table 1). The
potential for Ipilimumab to provide a clinical benefit in
these patients is limited since they are unable to receive
more than 1 or 2 cycles of the drug.
As a consequence, the BRAF mutated patients should
be approached, from a therapeutic point of view, consid-
ering the 2 groups: the slow and the fast progressors.Table 2 Proposed baseline factors to identify slow and
fast progressors
Slow progressor Fast progressor
PS 0 PS 1
Normal LDH Elevated LDH
Absence of brain metastasis Presence of brain metastasis
PS = Performance Status.The first group includes patients that, due to the kin-
etics of their illness, can be treated with both BRAF in-
hibitors and ipilimumab. In a recent publication, Jang
and Atkins [8] suggest treatment with ipilimumab first
in patients with indolent disease, while our hypothesis is
that patients with maximum one risk factor can benefit
from receiving BRAF inhibitor as the first part of their
sequential treatment regimen [5].
However, no data have yet shown which the best se-
quence is: considering the drug schedule, it could be
convenient to start with ipilimumab.
On the other hand, it is much more important to de-
fine the correct approach for fast progressors. Conside-
ring that pretreatment with BRAF inhibitors increases
(double) the numbers of this fast progressors population,
these patients are at high risk of not receiving a subse-
quent treatment with ipilimumab. This is the main rea-
son why, in our previous report, we suggested starting
with ipilimumab; moreover, our preliminary data showed
that even patients with negative prognostic factors were
able to receive ipilimumab and subsequent BRAF inhibi-
tor upon progression. In our proposed algorithm, rapid
or slow progressions of disease were evaluated according
to baseline factors and, although further data are needed,
in the absence of prospective clinical data to guide the
choice of treatment sequence, this could help in the treat-
ment decision (Table 2).
The next challenge will be to find some predictive
markers that could help to identify the two populations,
thus guiding whether a BRAF inhibitor or ipilimumab
should be used first in sequential therapy. Further infor-
mation could come from molecular studies performed
on biopsy at baseline and progression in patients treated
with B-Raf inhibitors. In the future, combination or
sequential approaches, with BRAF plus MEK or PI3K
inhibitors and different immunomodulating antibodies
(PD-1, anti-PD-L1) could increase the benefit for these
patients [9].
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